
Clinical investigation plan

The protocol of a medical device trial



Kazem Heidari

MD, PhD

Clinical Trial Center;

Tehran University of Medical Sciences

<http://ctc.tums.ac.ir>



What is a CIP?

- A document that state(s) the
 - Rationale
 - Objectives
 - Design
 - proposed analysis
 - Methodology
 - Monitoring
 - Conduct
 - record-keeping
- of the clinical investigation

Qualification

- **All parties** participating in the conduct of the clinical investigation shall be qualified by education, training or experience to perform their tasks
- This shall be **documented** appropriately

CIP development

- The CIP and all subsequent amendments to the CIP are agreed upon between
 - the sponsor
 - all principal and coordinating investigators
- are recorded with a justification for each amendment.

The contents of a CIP

- General
- Identification and description of the investigational device
- Justification for the design of the clinical investigation
- Risks and benefits of the investigational device and clinical investigation
- Objectives and hypotheses of the clinical investigation
- Design of the clinical investigation
- Statistical considerations
- Data management
- Amendments to the CIP
- Deviations from clinical investigation plan
- Device accountability
- Statements of compliance
- Informed consent process
- Adverse events, adverse device effects and device deficiencies
- Vulnerable population
- Suspension or premature termination
- Publication policy
- Bibliography

1. General information

- ❑ Identification of the clinical investigation plan
- ❑ Sponsor
- ❑ Principal investigator, coordinating investigator and investigation site(s)
- ❑ Overall synopsis of the clinical investigation

1.1: Identification of the CIP

- Title
- Reference number
- Version or date
- Summary of the revision history
- Page number and the total number of pages on each page.

1.2: Sponsor

- Name and address of the sponsor of the clinical investigation.
 - If the sponsor is not resident in the country in which the clinical investigation is to be carried out, the name and address of a **representative in that country** can be required according to national or regional regulations.

1.3: Investigators and site(s)

- ❑ Name, address, and professional position of principal and coordinating investigators
- ❑ Name and address of the investigation site(s)
- ❑ Name(s) and address(es) of other institutions involved

- ❑ The sponsor shall maintain an updated list of principal investigators, investigation sites, and institutions.

1.4: Overall synopsis

- All the relevant information regarding the clinical investigation design such as inclusion/exclusion criteria, number of subjects, duration of the clinical investigation, follow-up, objective(s) and endpoint(s).

- Useful to include a flow chart

Figure. Example template of recommended content for the schedule of enrolment, interventions, and assessments.*

TIMEPOINT**	STUDY PERIOD							
	Enrolment	Allocation	Post-allocation					Close-out
	$-t_1$	0	t_1	t_2	t_3	t_4	etc.	t_x
ENROLMENT:								
Eligibility screen	X							
Informed consent	X							
<i>[List other procedures]</i>	X							
Allocation		X						
INTERVENTIONS:								
<i>[Intervention A]</i>			←————→					
<i>[Intervention B]</i>			X		X			
<i>[List other study groups]</i>			←————→					
ASSESSMENTS:								
<i>[List baseline variables]</i>	X	X						
<i>[List outcome variables]</i>				X		X	etc.	X
<i>[List other data variables]</i>			X	X	X	X	etc.	X

2. Investigational device

- ❑ Description of the device and its intended purpose.
- ❑ Details concerning the manufacturer
- ❑ Name or number of the model/type, including software version and accessories.
- ❑ How traceability shall be achieved
- ❑ Intended purpose in the investigation.
- ❑ The intended populations and indications
- ❑ Description of the device including any materials that will be in contact with tissues or body fluids.
- ❑ Necessary training and experience needed to use the device.
- ❑ The specific medical or surgical procedures involved in the use of the device.

3. Justification for the design

- shall be based on the conclusions of the evaluation
 - an evaluation of the results of the **relevant pre-clinical testing/assessment** carried out to justify the use of the investigational device in human subjects
 - an evaluation of **clinical data** that are relevant to the proposed clinical investigation.

4. Risks and benefits

- ❑ Anticipated clinical benefits.
- ❑ Anticipated adverse device effects.
- ❑ Residual risks associated with the investigational device
- ❑ Risks associated with participation in the clinical investigation.
- ❑ Possible interactions with concomitant medical treatments.
- ❑ Steps that will be taken to control or mitigate the risks.
- ❑ **Risk-to-benefit rationale.**
 - The risk management process, which includes risk analysis, risk-to-benefit assessment and risk control is described in ISO 14971.

5. Objectives and hypotheses

- **Primary** and **secondary** objectives.
- **Hypotheses** to be accepted or rejected by statistical data from the clinical investigation.
- **Claims and intended performance** of the investigational device that are to be verified.
- **Risks** and anticipated adverse device effects that are to be assessed.

6. Design of the clinical investigation

- General
- Investigational device(s) and comparator(s)
- Subjects
- Procedures
- Monitoring plan

6.1: General

- ❑ Type of clinical investigation to be performed (e.g. comparative double-blind, parallel design, with or without a comparator group) with rationale
- ❑ The measures to be taken to minimize or avoid bias, including **randomization and blinding/masking**.
- ❑ Primary and secondary **endpoints**
- ❑ **Methods and timing** for assessing, recording, and analyzing variables.
- ❑ **Equipment to be used for assessing** the clinical investigation variables.
- ❑ Any procedures for the **replacement** of subjects.

6.2: Investigational device(s) and comparator(s)

- ❑ **Description** of the exposure to the investigational device(s) or comparator(s)
- ❑ Justification of the choice of **comparator(s)**.
- ❑ List of **any other medical device or medication** to be used during the clinical investigation.
- ❑ **Number of investigational devices** to be used, together with a justification.

6.3: Subjects

- Inclusion criteria
- Exclusion criteria
- Criteria and procedures for subject withdrawal
- Point of enrolment.
- Total duration of the investigation.
- Duration of each subject's participation.
- Number of subjects required
- Time needed to select this number

6.4: procedures

- ❑ All the **clinical-investigation-related procedures** that subjects undergo
- ❑ Activities performed by sponsor representatives (excluding monitoring).
- ❑ Any known or foreseeable factors that may **compromise the outcome** of the clinical investigation or the interpretation of results.
 - Baseline
 - Follow-up period
 - medical care

6.5: Monitoring plan

- General outline of the monitoring plan to be followed
 - Access to source data
 - The extent of source data verification planned.

- It is possible to provide a **detailed plan for monitoring arrangements** separately from the CIP.

7. Statistical considerations

- ❑ Statistical design, method and analytical procedures,
- ❑ **sample size,**
- ❑ the level of significance and the power
- ❑ expected drop-out rates,
- ❑ pass/fail criteria
- ❑ **Interim analysis**
- ❑ criteria for the termination of the investigation on statistical grounds,
- ❑ procedures for reporting any deviation from the original statistical plan,
- ❑ Subgroups for analysis,
- ❑ procedures that take into account all the data,
- ❑ **The treatment of missing, unused or spurious data**
- ❑ the exclusion of particular information from the testing of the hypothesis
- ❑ **Multicenter clinical investigations:** the minimum and maximum number of subjects to be included for each center.

8. Data management

- ❑ Procedures used for data review, database cleaning, and issuing and resolving data queries.
- ❑ Procedures for verification, validation and securing of electronic clinical data systems, if applicable.
- ❑ Procedures for data retention.
- ❑ Specified retention period.
- ❑ Other aspects of clinical quality assurance, as appropriate

9. Amendments to the CIP

- Description of the procedures to amend the CIP

10. Deviations from CIP

- Statement specifying that the investigator is not allowed to deviate from the CIP
 - Emergency conditions
- Procedures for recording, reporting and analyzing CIP deviations.
- Notification requirements and time frames.
- Corrective and preventive actions and principal investigator disqualification criteria.

11. Device accountability

- Description of the procedures for the accountability of investigational devices
 - the date of receipt,
 - identification of each investigational device (batch number/serial number or unique code)
 - the expiry date, if applicable,
 - the date or dates of use,
 - subject identification,
 - date on which the investigational device was returned/explanted from subject, if applicable
 - the date of return of unused, expired or malfunctioning investigational devices

12. Statements of compliance

- Statement specifying that
 - the clinical investigation shall be conducted in accordance with the **ethical** principles
 - compliance with this International Standard and any regional or national **regulations**
 - the clinical investigation **shall not begin** until the required approval/favourable opinion from the EC or regulatory authority have been obtained.
 - any **additional requirements** imposed by the EC or regulatory authority shall be followed
 - the type of **insurance** that shall be provided for subjects

13. Informed consent process

- Description of the **general process for obtaining informed consent**, including the process for providing subjects with new information, as needed.
- Description of the informed consent process in **circumstances where the subject is unable to give it**

14. Adverse events, adverse device effects and device deficiencies

- List of foreseeable
 - Adverse events
 - Adverse device effects
 - Device deficiencies

- Serious or not?

- unanticipated or not?

- Time period for report
- Process for reporting.
- Emergency contact details for reporting

15. Vulnerable population

- ❑ Description of the **vulnerable population**.
- ❑ Description of the specific **informed consent** process.
- ❑ Description of the **EC's specific responsibility**.
- ❑ Description of what **medical care**, if any, will be provided for subjects after the clinical investigation has been completed.

16. Suspension or premature termination

- Criteria and arrangements
 - the whole clinical investigation
 - in one or more sites.

- Criteria for access to and breaking the blinding/masking code

- Requirements for subject follow-up.

17. Publication policy

- ❑ Statement indicating whether the results of the clinical investigation will be submitted for publication.
- ❑ Statement indicating the conditions under which the results of the clinical investigation will be offered for publication.

18. Bibliography

- List of bibliographic references pertaining to clinical investigation.

Thank You!

Follow us

Website: ctc.tums.ac.ir

Telegram channel: [CTCacademy](https://t.me/CTCacademy)

